Avidity biosciences reports third quarter 2022 financial results and recent highlights

Company has three distinct rare disease programs in clinical development - myotonic dystrophy type 1 (dm1), facioscapulohumeral muscular dystrophy (fshd), and duchenne muscular dystrophy (dmd) on track for preliminary assessment of aoc 1001 marina™ trial in fourth quarter san diego , nov. 8, 2022 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced financial results for the third quarter ended september 30, 2022 and highlighted recent corporate progress.        "consistent with our guidance for 2022, we have progressed three programs addressing three distinct rare diseases into clinical development, and we remain on track for our preliminary assessment of the marina™ trial this quarter," said sarah boyce, president and chief executive officer.
RNA Ratings Summary
RNA Quant Ranking